ClearTrial Selected to Chair Cambridge Healthtech Institute's Strategic Resource Management Conference

Share Article

ClearTrial selected to chair session at leading life sciences conference; company also sponsoring presentation of capacity planning and forecasting research by the Tufts Center for the Study of Drug Development

News Image
A key component of our broader mission as a company is to provide a forum for thought leaders to share their own insights into helping the industry succeed in the current operating environment.

ClearTrial (http://www.cleartrial.com), the leading provider of Clinical Trial Operations (CTO) software, announced today that the company has been selected to serve as a conference chair for the Cambridge Healthtech Institute's (CHI) and BioPharma Strategy Series’ Strategic Resource Management conference, being held November 3-4 in Philadelphia. Held in conjunction with the CHI Portfolio Management conference, each year this executive forum attracts over 100 participants who help lead their organizations’ resource management, portfolio management, R&D, and commercial strategies.

Mindy Davis, Director, Clinical Services for ClearTrial, was selected by conference organizers to chair Day Two of the Strategic Resource Management conference. As chair, she will direct the conference proceedings for the day and contribute insights from more than 20 years in the life sciences industry to the day's discussion.

In addition, ClearTrial is sponsoring the presentation "Trends in Assessing Clinical Trial Costs and Resource Demand," by Stella Stergiopoulos of the Tufts Center for the Study of Drug Development. She will present summary findings from two Tufts CSDD research projects: a cross-functional capacity planning working group, and a study assessing the evolving role of capacity planning and forecasting – a new, as-yet unpublished study. ClearTrial is sponsoring this session to foster greater understanding of the trends and practices shaping drug development.

"A key component of our broader mission as a company is to provide a forum for thought leaders to share their own insights into helping the industry succeed in the current operating environment," said Andy Grygiel, Vice President of Marketing and Product Management for ClearTrial. "The Tufts Center for the Study of Drug Development has been at the forefront of this effort for more than 30 years, and we're pleased to be able to support the dissemination of their strategic knowledge."

The CHI Portfolio Management and Strategic Resource Management conferences are being held November 2-4 at the Crowne Plaza Philadelphia Downtown in Philadelphia. For more information or to register, visit http://www.healthtech.com/pfo or http://www.healthtech.com/sra.

About ClearTrial®
ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, linking clinical planning, forecasting, and tracking of operational and financial performance in a single, integrated system. ClearTrial’s award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

For more information contact:

Mike Lange
ClearTrial
+1 630.986.9800 x112
mlange(at)cleartrial(dot)com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mike Lange
ClearTrial
+1 630 986 9800 ext. 112
Email >
Visit website